Compare DOLE & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOLE | TRVI |
|---|---|---|
| Founded | 1851 | 2011 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2021 | 2019 |
| Metric | DOLE | TRVI |
|---|---|---|
| Price | $15.68 | $13.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | $15.00 | ★ $21.55 |
| AVG Volume (30 Days) | 586.8K | ★ 1.2M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.18% | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | ★ 0.53 | N/A |
| Revenue | ★ $9,172,907,000.00 | N/A |
| Revenue This Year | $4.54 | N/A |
| Revenue Next Year | $1.83 | N/A |
| P/E Ratio | $29.34 | ★ N/A |
| Revenue Growth | ★ 8.23 | N/A |
| 52 Week Low | $12.52 | $5.38 |
| 52 Week High | $16.51 | $14.39 |
| Indicator | DOLE | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 65.90 | 63.61 |
| Support Level | $15.60 | $10.07 |
| Resistance Level | $15.73 | $13.97 |
| Average True Range (ATR) | 0.36 | 0.88 |
| MACD | 0.18 | 0.22 |
| Stochastic Oscillator | 96.81 | 85.97 |
Dole PLC operates in the North American and European markets for fresh fruits and vegetables. The company's segment includes Fresh Fruit; Diversified Fresh Produce - EMEA; Diversified Fresh Produce - Americas and ROW. It generates maximum revenue from the Diversified Fresh Produce - EMEA segment. Diversified Fresh Produce - EMEA segment includes Dole's Irish, Dutch, Spanish, Portuguese, French, Italian, U.K., Swedish, Danish, South African, Eastern European, and Brazilian businesses, the majority of which sell a variety of imported and local fresh fruits and vegetables through retail, wholesale and, in some instances, food service channels across the European marketplace. Geographically, the company operates in United States, Ireland, U.K. Spain, Sweden, and Others.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.